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Abstract
Background: While there is extensive literature evaluating the impact of phytoestrogen consumption on breast
cancer risk, its role on ovarian cancer has received little attention.
Methods: We conducted a population-based case-control study to evaluate phytoestrogen intake from foods and
supplements and epithelial ovarian cancer risk. Cases were identified in six counties in New Jersey through the
New Jersey State Cancer Registry. Controls were identified by random digit dialing, CMS (Centers for Medicare and
Medicaid Service) lists, and area sampling. A total of 205 cases and 390 controls were included in analyses.
Unconditional logistic regression analyses were conducted to examine associations with total phytoestrogens, as
well as isoflavones (daidzein, genistein, formononetin, and glycitein), lignans (matairesinol, lariciresinol, pinoresinol,
secoisolariciresinol), and coumestrol.
Results: No statistically significant associations were found with any of the phytoestrogens under evaluation.
However, there was a suggestion of an inverse association with total phytoestrogen consumption (from foods and
supplements), with an odds ratio (OR) of 0.62 (95% CI: 0.38-1.00; p for trend: 0.04) for the highest vs. lowest tertile
of consumption, after adjusting for reproductive covariates, age, race, education, BMI, and total energy. Further
adjustment for smoking and physical activity attenuated risk estimates (OR: 0.66; 95% CI: 0.41-1.08). There was little
evidence of an inverse association for isoflavones, lignans, or coumestrol.
Conclusions: This study provided some suggestion that phytoestrogen consumption may decrease ovarian cancer
risk, although results did not reach statistical significance.
Background
Cancer of the ovary is the second most common gyne-
cologic cancer and the leading cause of death from
gynecologic malignancies [1]. While the etiology of ovar-
ian cancer is not well understood, a protective effect of
oral contraceptive use and higher parity is widely
accepted [2]. The main theories proposed to explain
ovarian pathogenesis are “incessant ovulation” proposed
by Fathalla [3] and excessive gonadotropin stimulation
of the ovarian epithelium proposed by Stadel [4]. Propo-
nents of the former theory argue that ovulation results
in minor trauma to the ovarian epithelium leading to
rapid proliferation to repair the ovulatory wound.
Abnormal proliferation or malignant transformation
may result from excess stimulation by hormonal factors,
such as estrogen-rich follicular fluid after ovulation or
excessive gonadotropin levels leading to stimulation by
estrogens or estrogen precursors [5]. There has also
been a growing interest in the role of inflammation on
ovarian cancer. Proponents of this theory argue that
repeated ovulation causes inflammation, which leads to
stress in the ovarian epithelial surface cells, predisposing
them to genetic damage and malignant transformation
[6]. Based on these theories and what we know about
ovarian cancer etiology, factors capable of affecting
gonadotropins or estrogens, including their synthesis,
* Correspondence: elisa.bandera@umdnj.edu
1Cancer Prevention and Control Program/Division of Surgical Oncology, The
Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New
Brunswick, NJ, USA
Full list of author information is available at the end of the article
Bandera et al. BMC Women?’?s Health 2011, 11:40
http://www.biomedcentral.com/1472-6874/11/40
© 2011 Bandera et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.metabolism, actions, or regulation, can potentially affect
ovarian cancer risk. The experimental evidence suggests
that phytoestrogens may affect gonadotropin and estro-
gen levels [7], as well as cytokine production [8].
Phytoestrogens are non-steroidal plant-derived com-
pounds, with a similar structure as endogenous estro-
gens, and capable of showing both estrogenic and
antiestrogenic effects [9,10]. Main dietary phytoestro-
gens are isoflavones (found mainly in soy products) and
lignans, more widely distributed in the Western diet
(found in flaxseed, grain/breads, nuts, coffee, tea, fruits,
and vegetables) [11]. Plant lignans are transformed by
the intestinal microflora into the enterolignans, entero-
diol and enterolactone, which are believed to be more
physiologically active than their precursors [12]. For
years, only two plant lignans were considered entero-
lignan precursors, secoisolariciresinol and matairesinol.
However, other plant lignans, lariciresinol and pinoresi-
nol, have now been shown to have high conversion rates
into enterolignans, while food content on these lignans
have only recently become available [13].
While there is an extensive literature evaluating the
impact of phytoestrogen consumption on breast cancer
risk, its role on ovarian cancer has received little atten-
tion [7]. Out of six studies that have examined the role
of main phytoestrogens or foods high in phytoestrogens
and ovarian cancer, five studies tended to suggest an
inverse association [14-20]. In contrast, a recent cohort
study in Sweden failed to find an association with phy-
toestrogen intake [21]. A meta-analysis including the
four studies that evaluated soy [15-18] also reported
reduced risk [22].
We conducted a population-based case-control study,
the NJ Ovarian Cancer Study, specifically designed to
evaluate phytoestrogens and ovarian cancer risk in New
Jersey, a population characterized by large ethnic diver-
sity. Consumption of foods high in phytoestrogens not
included in the Block food frequency questionnaire
(FFQ) (see Appendix 1) was ascertained and a detailed
phytoestrogen composition database [23] was used to
derive intake levels of all the major isoflavones and lig-
nans, as well as total phytoestrogens. Furthermore, we
ascertained and examined the role of phytoestrogen/iso-
flavone supplements on ovarian cancer risk.
Methods
The NJ Ovarian Cancer Study has been described in
detail elsewhere [24]. In summary, the study builds
upon the EDGE Study (Estrogen, Diet, Genetics, and
Endometrial Cancer), a population-based case-control
study based in New Jersey [25,26]. We used the controls
from the EDGE Study and added ovarian cancer cases
to form a new case-control study. Same eligibility cri-
teria and methods were carefully implemented in the
case and the control groups. Cases were newly diag-
nosed histologically confirmed cases of invasive epithe-
lial ovarian cancer identified between January 2004 and
May 2008 through rapid case ascertainment by the New
Jersey State Cancer Registry (NJSCR), a population-
based SEER cancer registry that has collected data since
1978. Women older than 21 years, able to understand
English or Spanish, and residing in one of six New Jer-
sey counties (Bergen, Essex, Hudson, Middlesex, Morris,
and Union) were eligible to participate. A total of 682
eligible cases were initially identified. Of them, 70 cases
were not contacted because they were deceased (n = 61)
or their physicians advised us not to contact them (n =
9). Additionally 119 people were ineligible because they
could not be reached, no longer met eligibility require-
ments, there was a communication barrier, or they
reported some other medical condition that precluded
participation. Of the 493 remaining cases, 252 consented
to participate (51%) and 233 completed the interview
(47%).
The control group was the same as in the EDGE
Study, described in detail elsewhere [24-27]. In brief,
controls had the same eligibility criteria as the cases
except that women with a history of hysterectomy and/
or bilateral oophorectomy were excluded from the ana-
lysis. Random digit dialing was employed to recruit
women under 65 years of whom 355 were eligible to
participate and 175 completed the interview. Women
older than 65 years were located through random selec-
tion by using lists purchased from the Center for Medi-
care and Medicaid Services (CMS); 68 women from this
source completed the study. Finally, an area sampling
approach identified 524 women older than 55 years who
were eligible to participate, out of whom 224 completed
the study. Overall, a total of 467 (approximately 40%)
controls from the three sources completed the study.
Informed consent was obtained from all participants,
and the study was approved by the Institutional Review
Boards at Robert Wood Johnson Medical School, Mem-
orial Sloan-Kettering Cancer Center, and the New Jersey
Department of Health and Senior Services.
Data Collection
We used the same procedures in the NJ Ovarian Cancer
Study and the EDGE Study to standardize data collec-
tion in cases and controls. Interviewers were trained
using the same procedures and same training manual.
Interviews, conducted by telephone for most respon-
dents, covered established and suspected risk factors for
ovarian cancer. In addition to the interview, participants
were mailed a package with instructions for providing
buccal specimens and waist and hip circumference mea-
surements and the Block 98.2 food frequency question-
naire (FFQ). Participants were instructed to report their
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ing the six months before diagnosis (for cases) or the
date of the interview (for controls). Two hundred and
five (88%) cases and 398 controls (85%) returned the
FFQ. The participants who returned the FFQ tended to
be older, but there were no significant differences in
education, oral contraceptive use, hormone replacement
therapy use, tubal ligation or family history of ovarian
cancer (data not shown). Eight of the controls were
excluded because both of their ovaries had been
removed, placing them at negligible risk of developing
ovarian cancer, resulting in 390 controls being included
in analyses.
The Block 98.2 FFQ (NutritionQuest, Berkeley, CA)
includes 110 food items and was developed using the
NHANES (National Health and Nutrition Examination
Survey) III dietary recall data. It also includes questions
on portion size for each food, and pictures are provided
to facilitate estimation. The questionnaire includes a
variety of foods containing phytoestrogens, such as sev-
eral kinds of beans, tofu, soymilk, canned tuna fish,
meat substitutes (e.g., veggieb u r g e r s ,v e g g i ec h i c k e n ) ,
and whole wheat bread. To supplement the list of foods,
we added one page with 21 additional food items, based
on the LACE questionnaire [28] and including other
food items that have been identified as important
sources of phytoestrogens [29]. The additional foods in
the supplemental page that we added, and that are not
included in the Block 98.2 questionnaire, are listed in
Appendix 1. We also asked about the use of phytoestro-
gen/soy supplements including frequency and duration
of use. NutritionQuest provided nutrient calculations
using the USDA Nutrient Database for Standard Refer-
ence. For phytoestrogen calculations we used a Cana-
dian database with detailed analyses of phytoestrogen
content of foods, including detailed values for lignans
[23]. Given the global food trading, we do not expect
major differences in lignan composition between foods
available in the United States and Canada.
Statistical Analysis
We evaluated the association of ovarian cancer risk with
total phytoestrogens, as well as with major phytoestro-
gen groups (isoflavones, lignans, and coumestan) and
specific phytoestrogens. This included isoflavones (daid-
zein, genistein, formononetin, and glycitein, and total
isoflavones calculated by summing those four isofla-
vones), lignans (matairesinol, lariciresinol, pinoresinol,
secoisolariciresinol and total lignans calculated by sum-
ming the four lignans), and coumestrol. Total phytoes-
trogen consumption was computed by adding total
isoflavones, total lignans and coumestrol. Age-adjusted
means were compared using ANCOVA. Participants
were categorized into tertiles of intake based on the
distribution of intake in controls. Odds ratios (OR) and
95% confidence intervals (CI) were estimated by uncon-
ditional multiple logistic regression. Tests for trend were
derived by assigning the median value to each tertile.
Potential confounding variables considered were age;
education (high school or less, college, graduate school);
race; age at menarche (continuous); menopausal status;
parity (0-1, 2, ≥ 3); oral contraceptive use (ever, never
used); use of hormone replacement therapy (HRT)
(never used any HRT, used unopposed estrogen only,
used combined therapy, i.e., estrogen and progesterone);
tubal ligation, BMI, calculated as weight (in kg) divided
by height (in m
2); total energy intake (as a continuous
variable), smoking status; alcohol use (g/1000 kcal); and
physical activity in metabolic equivalents (METs) for
reported average hours per week of strenuous or moder-
ate recreational activities. We adjusted for total energy
intake using the multivariate nutrient density model, by
computing nutrient density for each variable expressed
in mcg (or mg) per 1000 kcal of intake and including
total calories as a continuous variable in the model [30].
We repeated analyses adjusting for alcohol consump-
tion, but estimates essentially did not change. SAS ver-
sion 9.2 (SAS Institute, Cary NC) was used for analysis.
Results
Main characteristics of participants in the study are
shown in Table 1. The distribution according to main
factors affecting the risk of the disease was similar to
that reported in other studies, with higher parity and
having had a tubal ligation showing a particularly strong
inverse association.
Age-adjusted means for phytoestrogen and total calo-
ric intake in cases and controls are compared in Table
2. Total isoflavones, total lignans, and total phytoestro-
gen consumption, both from food only and from food
and supplements, were lower in cases than controls, but
none of the differences were statistically significant. As
expected, the major source of phytoestrogen consump-
tion in this population was lignans. Use of isoflavone/
phytoestrogen supplements was low in this population,
with only 5.4% of the cases and 4.9% of the controls
reporting to ever use them (p value: 0.84). Similarly, use
of soy powders was reported by only 6.3% of the cases
and 3.9% of the controls (p value: 0.19) (data not
shown).
Risk estimates for total phytoestrogens, isoflavones,
and lignans are shown in Table 3. After adjusting for
age, education, race, major reproductive risk factors,
BMI and total calories, there was a suggestion of a
decreased risk with phytoestrogen consumption, with an
OR of 0.62 (95% CI: 0.38-1.00; p for trend: 0.04) for the
highest tertile of total phytoestrogen intake from foods
and supplements compared to the lowest. Further
Bandera et al. BMC Women?’?s Health 2011, 11:40
http://www.biomedcentral.com/1472-6874/11/40
Page 3 of 9Table 1 Selected characteristics of women participating in the NJ Ovarian Cancer Study
Cases (n = 205)
n (%)
Controls (n = 391)
n (%)
OR (95% CI)*
Education
High school or less 61 (29.8) 133 (34.0) 1.00 (Ref)
College 93 (45.4) 159 (40.7) 0.90 (0.59-1.38)
Graduate school 51 (24.9) 99 (25.3) 0.76 (0.47-1.24)
Race/ethnicity
White 179 (87.3) 344 (88.4) 1.00 (Ref)
Black 9 (4.4) 17 (4.4) 1.02 (0.42-2.44)
Other 8 (3.9) 17 (4.4) 0.82 (0.33-1.99)
Hispanic (any race) 9 (4.4) 11 (2.8) 1.13 (0.44-2.92)
BMI
Underweight (< 18.5) 1 (0.5) 1 (0.3) 1.02 (0.06-17.31)
Normal (18.5-25) 90 (43.9) 180 (46.4) 1.00 (Ref)
Overweight (25-29.9) 54 (26.3) 122 (31.4) 1.07 (0.69-1.65)
Obese (30-34.9) 36 (17.6) 59 (15.2) 1.39 (0.83-2.32)
Very obese (≥ 35) 24 (11.7) 26 (6.7) 1.54 (0.81-2.89)
Parity
0 - 1 97 (47.3) 92 (23.5) 1.00 (Ref)
2 60 (29.3) 137 (35.0) 0.45 (0.29-0.69)
≥ 3 48 (23.4) 162 (41.4) 0.42 (0.26-0.66)
Smoking status
Never 108 (52.7) 204 (52.2) 1.00 (Ref)
Past 78 (38.1) 149 (38.1) 1.12 (0.76-1.64)
Current 19 (9.3) 38 (9.7) 0.87 (0.46-1.62)
Oral contraceptive use
Never 85 (41.5) 193 (49.4) 1.00 (Ref)
Ever 120 (58.5) 198 (50.6) 0.88 (0.61-1.28)
Use of HRT
Never 159 (77.6) 285 (72.9) 1.00 (Ref)
Unopposed E only 22 (10.7) 34 (8.7) 1.56 (0.86-2.84)
Any combined HRT 24 (11.7) 72 (18.4) 0.63 (0.38-1.06)
Age at menarche
> 13 41 (20.1) 99 (25.4) 0.81 (0.51-1.27)
12-13 117 (57.4) 200 (51.3) 1.00 (Ref)
≤11 46 (22.6) 91 (23.3) 0.75 (0.48-1.17)
Menopause status
Premenopausal 71 (34.6) 49 (12.5) 1.51 (0.85-2.69)
Postmenopausal
Age at menopause
< 40 5 (2.4) 14 (3.6) 0.77 (0.26-2.31)
41-54 86 (42.0) 239 (61.3) 1.00 (Ref)
≥ 55 12 (5.9) 37 (9.5) 0.99 (0.48-2.01)
Unknown 31 (15.1) 52 (13.3) 1.52 (0.91-2.56)
Tubal Ligation
No 175 (85.4) 315 (80.6) 1.00 (Ref)
Yes 30 (14.6) 76 (19.4) 0.59 (0.36-0.94)
First relative with ovarian cancer
No 195 (95.1) 377 (96.4) 1.00 (Ref)
Yes 10 (4.9) 14 (3.6) 1.32 (0.55-3.17)
*Adjusted for age
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estimates, with an OR of 0.66 (95% CI: 0.41- 1.08; p for
trend: 0.11). Adding alcohol intake to the model did not
change risk estimates (data not shown). There was little
evidence of an association for isoflavones or lignans, as
shown in Table 3. The OR for the highest vs. the lowest
tertile of total lignan intake was 1.10 (95% CI: 0.68-
1.79). There was no evidence of an association for cou-
mestrol (data not shown).
We further explored the association with the major food
sources of isoflavones, soy products (data not shown).
Intake was low in this population and, therefore, we were
only able to categorize women into ever vs. never consu-
mers for individual soy foods. There was a suggestion of a
decreased risk for tofu and total soy products. However,
after including smoking and physical activity in the model
with all the other major risk factors, the confidence inter-
val included one. For total soy products, the OR for those
consuming more than one cup per month of soy products
compared to never users was 0.71 (95% CI: 0.42-1.20).
Discussion
In this study we found a suggestion of an inverse asso-
ciation between phytoestrogen consumption and ovarian
cancer risk. However, confidence intervals included the
null value after adjusting for covariates, including physi-
cal activity and smoking. Estimates were stronger when
combined intake from foods and supplements was eval-
uated. Similarly, there was some suggestion of an inverse
association with tofu and combined soy product con-
sumption, but confidence intervals included one.
Few epidemiologic studies have evaluated the associa-
tion between phytoestrogens and ovarian cancer and, to
our knowledge, this is the first population-based study
to undertake a detailed analysis of lignans, isoflavones,
and total phytoestrogens in relation to ovarian cancer
risk in the United States, as well as attempting to com-
pute total phytoestrogens from foods and supplements.
Total isoflavone intake was previously evaluated in two
cohort studies in California [16] and Sweden [21] and
two hospital-based studies conducted in China [15] and
I t a l y[ 1 8 ] .T h r e eo ft h e s es t u d i e s[ 1 5 , 1 6 , 1 8 ]f o u n da n
inverse association with isoflavone intake, with approxi-
mately 50% reduced risk for the highest category of con-
sumption compared to the lowest. However, in the
cohort study in Sweden [21], like in our study, there
was little evidence of an association. Tofu was also eval-
uated in the California Teachers Cohort [16] and in the
Japan Collaborative Cohort (JACC) Study [17]. Similar
to our findings, both studies found risk estimates below
one, but the confidence interval included the null. Tofu
and meat substitutes were uncommonly used in both
our study and in the California Teachers Cohort, and
that may have affected our ability to detect an
Table 2 Age-adjusted mean phytoestrogen and caloric intake in cases and controls
From food
Compound (mcg/1000 kcal) Cases
Mean (SE)
Controls
Mean (SE)
p value
Total isoflavones 805.67 (182.55) 1154.43 (130.17) 0.13
Daidzein 332.61 (72.92) 451.45 (51.99) 0.20
Genistein 438.91 (105.10) 657.37 (74.94) 0.10
Formononetin 6.95 (0.49) 6.70 (0.35) 0.69
Glycitein 27.10 (6.92) 38.78 (4.93) 0.18
Total lignans 569.26 (40.48) 623.90 (28.86) 0.28
Matairesinol 3.90 (0.13) 3.77 (0.10) 0.44
Lariciresinol 34.21 (1.33) 37.14 (0.95) 0.08
Pinoresinol 24.59 (1.13) 26.12 (0.81) 0.28
Secoisolariciresinol 506.56 (40.22) 556.88 (28.68) 0.32
Coumestrol 0.85 (0.04) 0.87 (0.03) 0.68
Total phytoestrogens 1375.55 (188.90) 1778.97 (134.69) 0.09
Total calories (kcal) 1598.9 (47.97) 1602.3 (34.15) 0.95
From food and supplements
Total isoflavones 1513.06 (437.96) 2230.59 (312.28) 0.19
Total phytoestrogens 2082.94 (441.70) 2855.13 (314.95) 0.16
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Page 5 of 9Table 3 Isoflavone and total phytoestrogen intake and ovarian cancer risk in the NJ Ovarian Cancer Study
Cases
(n)
Controls
(n)
OR1 95% CI OR2 95% CI
FROM FOOD
Daidzein (mcg/1000 kcal)
1 (< 20.25) 58 129 1.00 1.00
2 (20.25-144.07) 86 131 1.29 0.81-2.06 1.34 0.83-2.16
3( ≥ 144.08) 61 130 0.80 0.48-1.31 0.88 0.53-1.46
p for trend 0.10 0.21
Genistein (mcg/1000 kcal)
1 (< 40.46) 62 129 1.00 1.00
2 (40.46-247.85) 82 132 1.17 0.74-1.86 1.22 0.76-1.96
3( ≥ 247.86) 61 129 0.75 0.46-1.23 0.83 0.50-1.38
p for trend 0.09 0.21
Formononetin (mcg/1000 kcal)
1 (< 3.90) 78 130 1.00 1.00
2 (3.90-6.80) 75 130 1.01 0.64-1.59 1.02 0.64-1.62
3( ≥ 6.81) 52 130 0.69 0.42-1.14 0.72 0.43-1.22
p for trend 0.11 0.17
Glycitein (mcg/1000 kcal)
1 (< 2.14) 67 130 1.00 1.00
2 (2.14-9.17) 72 131 0.98 0.62-1.57 0.95 0.59-1.53
3( ≥ 9.18) 66 129 0.74 0.46-1.21 0.80 0.48-1.33
p for trend 0.18 0.38
Total Isoflavones (mcg/1000 kcal)
1 (< 70.06) 61 129 1.00 1.00
2 (70.06-404.66) 83 132 1.20 0.76-1.92 1.24 0.77-2.00
3( ≥ 404.67) 61 129 0.78 0.48-1.27 0.86 0.52-1.42
p for trend 0.11 0.24
Matairesinol (mcg/1000 kcal)
1 (< 2.82) 69 129 1.00 1.00
2 (2.82-4.22) 69 131 1.05 0.66-1.67 1.00 0.68-1.78
3( ≥ 4.23) 67 130 1.41 0.88-2.27 1.58 0.97-2.58
p for trend 0.14 0.06
Lariciresinol (mcg/1000 kcal)
1 (< 27.17) 80 130 1.00 1.00
2 (27.17-40.01) 68 131 0.99 0.62-1.57 1.04 0.65-1.66
3( ≥ 40.02) 57 129 0.98 0.60-1.59 1.06 0.64-1.74
p for trend 0.93 0.83
Pinoresinol (mcg/1000 kcal)
1 (< 18.08) 84 129 1.00 1.00
2 (18.08-28.50) 62 132 0.76 0.48-1.20 0.80 0.50-1.29
3( ≥ 28.51) 59 129 0.92 0.58-1.48 0.97 0.59-1.58
p for trend 0.78 0.94
Secoisolariciresinol mcg/1000 kcal)
1 (< 193.64) 63 130 1.00 1.00
2 (193.64-624.92) 84 131 1.27 0.80-2.01 1.33 0.83-2.13
3( ≥ 624.93) 58 129 1.12 0.69-1.80 1.11 0.68-1.81
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study [15], which had a wider range of intake, soy foods
were also found to decrease ovarian cancer risk, with an
OR of 0.50 (95% CI: 0.31-0.82) [15].
We are aware of two other studies reporting on lignan
intake and ovarian cancer risk, with conflicting results.
The first is a case-control study in Western New York,
which evaluated two lignans combined, secoisolariciresi-
nol and matairesinol, and found a strong inverse asso-
ciation with intake [20]. The second study, is a cohort
study in Sweden [21] which, like ours, found no indica-
tion of an association with lignan consumption. Lignan
calculations were computed using different databases in
the three studies and this, together with possibly
Table 3 Isoflavone and total phytoestrogen intake and ovarian cancer risk in the NJ Ovarian Cancer Study (Continued)
p for trend 0.81 0.90
Total lignans (mcg/1000 kcal)
1 (< 271.22) 67 129 1.00 1.00
2 (271.22-704.75) 79 131 1.21 0.77-1.91 1.23 0.77-1.97
3( ≥ 704.76) 59 130 1.12 0.70-1.79 1.10 0.68-1.79
p for trend 0.77 0.84
Total phytoestrogens (mcg/1000 kcal)
1 (< 532.28) 80 130 1.00 1.00
2 (532.28-1287.81) 68 131 0.79 0.50-1.25 0.73 0.46-1.16
3( ≥ 1287.82) 57 129 0.68 0.42-1.08 0.73 0.45-1.19
p for trend 0.12 0.29
FROM FOOD and SUPPLEMENTS
Daidzein (mcg/1000 kcal)
1 (< 21.40) 59 130 1.00 1.00
2 (21.40-167.32) 90 131 1.35 0.85-2.15 1.40 0.87-2.26
3( ≥ 167.33) 56 129 0.73 0.44-1.21 0.82 0.49-1.38
p for trend 0.03 0.10
Genistein (mcg/1000 kcal)
1 (< 41.14) 60 130 1.00 1.00
2 (41.14-275.32) 86 131 1.25 0.78-1.99 1.31 0.82-2.11
3( ≥ 275.33) 59 129 0.82 0.50-1.34 0.92 0.55-1.54
p for trend 0.14 0.34
Glycitein (mcg/1000 kcal)
1 (< 2.17) 67 129 1.00 1.00
2 (2.17-11.64) 77 132 1.00 0.63-1.58 0.96 0.60-1.54
3( ≥ 11.65) 61 129 0.70 0.43-1.15 0.76 0.46-1.25
p for trend 0.11 0.24
Total Isoflavones (mcg/1000 kcal)
1 (< 71.80) 60 130 1.00 1.00
2 (71.80-497.97) 86 130 1.29 0.81-2.05 1.35 0.84-2.17
3( ≥ 497.98) 59 130 0.78 0.47-1.28 0.88 0.53-1.46
p for trend 0.08 0.21
Total phytoestrogens (mcg/1000 kcal)
1 (< 534.35) 79 130 1.00 1.00
2 (534.35-1395.56) 74 130 0.88 0.56-1.38 0.82 0.52-1.30
3( ≥ 1395.57) 52 130 0.62 0.38-1.00 0.66 0.41-1.08
p for trend 0.04 0.11
OR1: adjusted for age (continuous), education, race, age at menarche (continuous), menopausal status, parity, OC use, HRT use, BMI (continuous), tubal ligation,
and total calories (see methods for more details).
OR2: further adjusted for physical activity (METs for average hours of strenuous or moderate recreational activities per week) and smoking (smoking status and
pack-years for current & past smokers). Further adjustment for alcohol intake did not change risk estimates
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Page 7 of 9different food sources, may have explained, at least in
part, the discrepant findings.
Several mechanisms have been postulated to explain
the potential protective effect of soy and phytoestrogens
on ovarian carcinogenesis. They have been shown to
inhibit enzymes that synthesize and metabolize estro-
gens and increase sex hormone-binding globulin synth-
esis [22]. In addition, they are capable of binding to the
estrogen receptor (ER), particularly ER beta, which has
been involved in the differentiation of proliferating tis-
sue [22]. Other anticarcinogenic properties that have
been attributed to phytoestrogens include inhibiting
tumor angiogenesis, cell proliferation, tyrosine kinase,
and topoisomerase II [22].
Our study is subject to the limitations of case-con-
trol studies, such as potential recall bias, as cases may
report or recall dietary intake in a different way than
controls. However, because the relationship of ovarian
cancer with soy foods is largely unknown, and lignans
are widely distributed in the diet, this is unlikely. The
response rate in our study was low. However, it is well
known that participation rates in population-based stu-
dies have been decreasing over the past years, and
rates around 50% are not unusual, particularly among
controls [31]. To evaluate possible selection bias, we
compared the characteristics of women consenting to
participate in the study to all women diagnosed with
epithelial ovarian cancer using New Jersey State Cancer
Registry data in the same counties during a similar time
period [32]. Race and ethnic distribution was similar,
while the cases consenting tended to be younger, with a
median age of 56 years at diagnosis, compared to a med-
ian age of 61 years at diagnosis for the total population
of cases. The distribution by histology, stage, and grade
was generally similar. For controls, like most epidemio-
logic studies, we do not have information on those who
could not be reached or did not participate. However,
the distribution of the main risk factors for ovarian can-
cer in cases and controls is similar to that reported in
other studies. Furthermore, non-response bias would
only affect the study validity if willingness to participate
is related to the factors under evaluation [31,33]. The
possible role of dietary factors in the etiology of ovarian
cancer is not well known, and even less so that of phy-
toestrogens and soy foods. This reduces the possibility
of response bias. Also, the fact that our results are in
agreement with the current literature in this area lessens
even further the concern over possible non-response
bias.
Our sample size was relatively small and we may
have lacked power to detect a significant association.
Nevertheless, our results were in general agreement
with other studies. A major strength of our study is
that it was specifically designed to evaluate the
association between phytoestrogen intake from foods
and supplements and ovarian cancer risk. For
example, we expanded the questionnaire to include
important sources of these compounds. We also com-
puted all the major phytoestrogens for a detailed
assessment.
Future studies should conduct a comprehensive
assessment by including all major sources of phytoestro-
gens (including a detailed assessment of phytoestrogens
in supplements) and should have sufficient power to
evaluate the association, preferably using a prospective
design, which avoids the major biases inherent to the
case-control approach (such as recall and selection bias).
Conclusions
Although comparison of results across studies is chal-
lenging due to differences in methods and study popula-
tions, our findings, together with the few studies
published in this area, suggest that soy and phytoestro-
gen may decrease ovarian cancer risk.
Appendix 1 - Additional food items, not included
in the Block Food Frequency Questionnaire
(version 98.2)
Soy yogurt
Frozen soy yogurt
Soy ice cream
Soy cheese
Soy hot dogs/cold cuts
Other soy meat substitutes
Cooked soybeans or edamame
Roasted soy nuts
Tempeh
Miso soup
Alfalfa sprouts
Soybean sprouts
Protein powders made from soy protein isolate
Soy milk (included in the Block FFQ but it was
included again in the supplemental foods page)
Green tea
Garbanzo beans, chick peas, ceci beans or hummus
Dried fruit (e.g., apricots, raisins, prunes)
Seaweed
Sunflower seeds
Black licorice
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